Neil J. Robinson

Learn More
Note: Most SVRC technical reports are available via anonymous ftp, Abstract This paper describes the results to date of a feasibility study on model checking applied to railway interlockings. Our approach , in contrast to others, targets a high-level description of interlocking systems, namely the logical view of its operation. The result is a formal model(More)
SMT C1100 is a small molecule utrophin modulator in development to treat Duchenne muscular dystrophy. This study evaluated the safety, tolerability, and pharmacokinetics of SMT C1100 in healthy volunteers. This double-blind, placebo-controlled Phase 1 study comprised: Part 1, an escalating, single-dose with/without fasting involving 50 mg/kg, 100 mg/kg, 200(More)
We investigated the changes in both performance and selected physiological parameters following a Live High-Train Low (LHTL) altitude camp in either normobaric hypoxia (NH) or hypobaric hypoxia (HH) replicating current "real" practices of endurance athletes. Well-trained triathletes were split into two groups (NH, n = 14 and HH, n = 13) and completed an(More)
A medical and scientific multidisciplinary consensus meeting was held from 29 to 30 November 2013 on Anti-Doping in Sport at the Home of FIFA in Zurich, Switzerland, to create a roadmap for the implementation of the 2015 World Anti-Doping Code. The consensus statement and accompanying papers set out the priorities for the antidoping community in research,(More)
BACKGROUND Clostridium difficile infection (CDI) is a leading cause of diarrhoea in health care settings with symptoms ranging from mild and self-limiting to life threatening. SMT19969 is a novel, non-absorbable antibiotic currently under development for the treatment of CDI. Here we report the results from a Phase I study. METHODS A double-blind,(More)
BACKGROUND The FIFA has implemented an important antidoping programme for the 2014 FIFA World Cup. AIM To perform the analyses before and during the World Cup with biological monitoring of blood and urine samples. METHODS All qualified players from the 32 teams participating in the World Cup were tested out-of-competition. During the World Cup, 2-8(More)
PURPOSE SMT C1100 is a utrophin modulator being evaluated as a treatment for Duchenne muscular dystrophy (DMD). This study, the first in pediatric DMD patients, reports the safety, tolerability and PK parameters of single and multiple doses of SMT C1100, as well as analyze potential biomarkers of muscle damage. METHODS This multicenter, Phase 1 study(More)